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OBJECTIVES: Caspofungin was non-inferior to liposomal
amphotericin-B (L-AmB) in a recently conducted double-blind,
randomized clinical trial (RCT) in 1095 hematology/oncology
patients with persistent fever and neutropenia. Fewer patients
developed nephrotoxicity with caspofungin than with L-AmB
(2.6% vs. 11.5%, p < 0.001; Walsh et al., 2004). Based on the
RCT data, cost and consequences of treatment with caspofun-
gin versus L-AmB for empirical therapy of suspected systemic
fungal infection were determined for the German hospital
setting. METHODS: Our model is based on: (i) RCT nephro-
toxicity rates; (ii) prolonged length of hospital stay due to
nephrotoxicity in hematology/oncology patients in Europe (5.3
days, accounting perspective, 95%CI 1.6;9.1, p = 0.004;
Ullmann et al., 2006); and (iii) bottom-up data on direct cost of
hematology/oncology stay per day. Bootstrapping and Monte-
Carlo simulations were performed (SAS 9.1.3, WinBUGS 1.4.1).
Calculations were based on patient-individualized doses per
treatment episode per RCT treatment arm (Caspofungin 13 days;
L-AmB 12.5 days; 70 kg patient), on both, ofﬁcial German price
list, and German high-user hospital antifungal acquisition cost.
RESULTS: The number needed to treat for one patient to be
harmed due to nephrotoxicity for L-AmB versus caspofungin
was 12 (95%CI 8;17). The nephrotoxicity-related prolongation
of hospital stay per patient was 0.48 days (95%CI 0.14;0.88).
Based on ofﬁcial list prices, caspofungin was cost-saving com-
pared to L-AmB. Based on high-user hospital pharmacy acquisi-
tion cost and cost from longer stay in hospital due to L-AmB
nephrotoxicity, caspofungin was cost-saving at hospital cost per
day of ≥€670, and ≥€1060, respectively, with and without
“Zusatzentgelt” (2006), a partial compensation German hospi-
tals can apply for to cover cost of caspofungin and L-AmB.
CONCLUSIONS: This model provides a framework for hospi-
tal-based economic evaluations of two different antifungal
agents with respect to tolerability and length of hospital stay.
Such evaluations can improve the quality of medical care and
help to thoughtfully allocate resources.
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OBJECTIVE: Chronic Hepatitis B (CHB) can lead to cirrhosis
and hepatocellular carcinoma. This study aims to estimate
resource utilisation (RU) and costs associated with CHB 
management in Sweden, from a health-system perspective.
METHODS: Medical management patterns were estimated for:
Chronic Hepatitis B (CHB), Compensated Cirrhosis (CC),
Decompensated Cirrhosis (DC), and Hepatocellular Carcinoma
(HC). Resources considered were physician visits, drug therapy,
lab tests, diagnostic/therapeutic procedures and hospitalisation.
RU data were obtained from a Delphi panel of 5 hospital spe-
cialists. Complications considered for DC were: ascites, variceal
haemorrhage, hepatic encephalopathy, and bacterial peritonitis.
For HC, RU was estimated for the ﬁrst year post identiﬁcation
of the cancer. Based on RU, 2005 direct costs were estimated per
health state. RESULTS: Resource utilisation increased across
disease states, reﬂecting disease progression. The average annual
cost (range) of each state was: CHB: SEK 8001 (SEK 1891—SEK
17,011); CC: SEK 34,649 (SEK 7378—SEK 93,185); DC: SEK
135,783 (SEK 20,171—SEK 442,785); HC: SEK 280,009 (SEK
52,759—SEK 619,031); Average LT cost was SEK 668,027. Hos-
pitalisation is a key cost driver in DC and HC states. No GP
visits were reported. Hospital admissions were unneeded in the
CHB state. For CC, 5.8% of patients needed 1.25 admissions
(average 0.08) and in DC, 68% needed 2 admissions (average
1.4). In HC state, all patients were admitted on average 3.4
times. Average LOS in DC and HC states was 11 days. 35% of
HC patients needed hospice admission with an average LOS of
38 days. Common procedures include paracentesis (60%), scle-
rotherapy (50%), and TIPS (30%) in the DC state, and para-
centesis (70%), radiofrequency ablation (15%), and ethanol
injection (10%) in HC. CONCLUSIONS: RU and costs increase
with disease progression: costs for the HC state are more than
30 times those for the CHB stage.
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OBJECTIVE: To assess, in a real life setting, the predictive valid-
ity of a health-economic model that had been applied for the
Belgian reimbursement submission of voriconazole in proven
and probable invasive aspergillosis. METHODS: An observa-
tional study was designed to prospectively collect health-eco-
nomic data of patients with invasive aspergillosis starting
treatment with voriconazole. The same direct costs as in the
model were considered: costs for hospital stay, diagnostic pro-
cedures, treatment/monitoring of side effects, outpatient care and
use of anti-fungal drug(s). Resource utilization, expressed in
physical units, was multiplied with unit costs from the public
payer’s perspective. Costs were expressed as total costs and costs
for switchers/non-switchers from initial voriconazole treatment.
Effectiveness was expressed as clinical response and survival rate
at day 84. RESULTS: A total of 115 patients were included. The
average total cost was €14,153 (C.I.: €11,493; €16,812). This
was below the cost predicted by the model (€21,298). The dif-
ference was mainly caused by shorter hospitalization in this
study (9.59 days) than assumed in the model (29.4 days). On
average the total cost for switchers/non-switchers amounted to
€16,216/€10,067 in this study, which was below the estimated
cost of €27,586/€18,783 in the model, mainly due to a lower
hospitalization cost. The clinical response rate (50% successful
outcome) as well as the infection related survival rate (86.7%)
were in line with the ones applied in the model and reported
from the clinical trials (52% and 87.5% respectively). The
overall survival rate was lower compared to the model (58% vs.
70.8%), likely due to treating patients with poor prognosis at
baseline who would have been excluded from the clinical trial.
CONCLUSIONS: This observational study demonstrated that
the health-economic model provided an overestimate of the real
